Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 10;142(23):10526-10533.
doi: 10.1021/jacs.0c03592. Epub 2020 May 29.

Two-Phase Synthesis of Taxol

Affiliations

Two-Phase Synthesis of Taxol

Yuzuru Kanda et al. J Am Chem Soc. .

Abstract

Taxol (a brand name for paclitaxel) is widely regarded as among the most famed natural isolates ever discovered, and has been the subject of innumerable studies in both basic and applied science. Its documented success as an anticancer agent, coupled with early concerns over supply, stimulated a furious worldwide effort from chemists to provide a solution for its preparation through total synthesis. Those pioneering studies proved the feasibility of retrosynthetically guided access to synthetic Taxol, albeit in minute quantities and with enormous effort. In practice, all medicinal chemistry efforts and eventual commercialization have relied upon natural (plant material) or biosynthetically derived (synthetic biology) supplies. Here we show how a complementary divergent synthetic approach that is holistically patterned off of biosynthetic machinery for terpene synthesis can be used to arrive at Taxol.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Approaches to the synthesis of Taxol (1): Semi-synthesis, canonical total synthesis, biosynthesis, and two-phase synthesis (this work).
Scheme 1.
Scheme 1.. Two-phase synthesis of 1.
Reagents and conditions are as follows. (a) Cr(V) (16), HFIP, TMSOH, t-BuOH, 80 °C. (b) CuBr2, THF, rt, 55%, over 2 steps. (c) NBS, BPO, CCl4, then DTBMP, AgOTf, TESOH, 4Å MS, PhMe, rt, 68%. (d) LiBr, Li2CO3, DMF, 100°C, 88%. (e) MeMgBr, DCM, 0 °C to rt, then DIBAL, −78 °C, DCM, then LiAlD4, THF, 60 °C, 74%. (f) NaHMDS, TBSCl, THF, 0 °C to rt, 94%. (g) DMDO, 0 °C, 49%. (h) TPAP, NMO, DCM, rt, 81%. (h) Na, i-PrOH, Et2O, rt, then triphosgene, pyr, DMAP, DCM, −78 to 0 °C. (j) TBAI, BF3•OEt2, DCM, −78 °C, then 2-Fpyr, −78 °C, then TMSIm, rt, then DMDO, −78 °C to rt, 43%. (k) Cp2TiCl, Et3SiH, THF, −78 °C to rt, 67%. (l) BOMCl, TBAI, DIPEA, DCE, 45 °C, 84%. (m) Burgess reagent, PhMe, dioxane, then HF, H2O, pyr, MeCN, rt, 32%. (n) MsCl, pyr, 0 °C to rt, then OsO4, THF, pyr, 0 °C to rt, 68%. (o) DIPEA, PhMe, then IBX, DMSO, H2O, 80 °C, 62%. (p) KOt-Bu, (PhSeO)2O, THF, H2O, −78 to 0 °C, 73%. (q) KOt-Bu, THF, then triphosgene, pyr, DMAP, DCM, −78 to 0 °C, then Ac2O, DMAP, pyr, rt, 60%. (r) TASF, THF, rt, then PhLi, THF, −78 °C, 48%. (s) β-lactam (35), LHMDS, THF, −78 °C to rt, then Pd/C, H2, EtOH, 80 °C, 85%.; HFIP, hexafluoroisopropanol; TMSOH, trimethylsilanol; NBS, N-bromosuccinimide; BPO, benzoyl peroxide; DTBMP, 2,6-di-tert-butyl-4-methylpyridine; TESOH, triethylsilanol; DIBAL, diisobutylaluminium hydride; HMDS, hexamethyldisilazane; TBSCl, t-butyldimethylsilyl chloride; DMDO, dimethyldioxirane; TPAP, tetrapropylammonium perruthenate; NMO, N-methylmorpholine N-oxide; pyr, pyridine; DMAP, 4-dimethylaminopyridine; TBAI, tetra-n-butylammonium iodide; 2-Fpyr, 2-fluoropyridine; TMSIm, N-(trimethylsilyl)imidazole; Cp2TiCl, bis(cyclopentadienyl)titanium(III) chloride; BOMCl, benzyl chloromethyl ether; DIPEA, N,N-diisopropylethylamine; DCE, 1,2-dichloroethane; MsCl, methanesulfonyl chloride; IBX, 2-iodoxybenzoic acid; TASF, tris(dimethylamino)sulfonium difluorotrimethylsilicate.

Similar articles

Cited by

References

    1. Nicolaou KC; Montagnon T Molecules That Changed the World: A Brief History of the Art and Science of Synthesis and Its Impact on Society, 1st ed.; Wiley-VCH: Weinheim, 2008.
    1. Brickley P NIH Censured for Taxol Deal. Genome Biol. 2003, 4 (1).
    1. Celgene. Press Release Archive. 2020, https://ir.celgene.com/press-releases-archive/defa.
    1. Commerçon A; Bézard D; Bernard F; Bourzat JD Improved Protection and Esterification of a Precursor of the Taxotere® and Taxol Side Chains. Tetrahedron Lett. 1992, 33 (36), 5185–5188.
    1. Drug Approval Package: Taxotere (Docetaxel) #020449s028 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-449s028_Taxot... (accessed Feb 11, 2020).

Publication types

MeSH terms

Substances